Chronic Kidney Diseases
Illuminating the CKD Patient Journey: Clinicogenomic Data Reshapes Research & Drug Discovery
chronic kidney disease; CKD; clinicogenomics; drug discovery; cell therapy; gene therapy; clinical trials; personalized medicine
AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat
AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry
FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease
Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist
Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs
Maze Therapeutics, Series D funding, kidney disease, clinical-stage programs, precision medicine, APOL1 kidney disease, chronic kidney disease, MZE829, MZE782.
Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks
Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring
FDA Advisory Committee Rejects Lexicon’s Zynquista for Type 1 Diabetes and Chronic Kidney Disease
FDA, Lexicon Pharmaceuticals, Zynquista, sotagliflozin, type 1 diabetes, chronic kidney disease, FDA advisory committee, drug approval
FDA Advisory Committee Votes Against Zynquista for Type 1 Diabetes and Chronic Kidney Disease, Despite Support for Subgroup Benefits
FDA Advisory Committee, Zynquista (sotagliflozin), Type 1 Diabetes (T1D), Chronic Kidney Disease (CKD), Glycemic Control, SGLT1/SGLT2 Inhibitor, Lexicon Pharmaceuticals
ProKidney Streamlines Phase 3 Program to Expedite U.S. Approval of Rilparencel for Chronic Kidney Disease
ProKidney, rilparencel, chronic kidney disease, CKD, cell therapy, RMAT designation, FDA approval, Phase 3 trial
ProKidney Suspends One Phase 3 CKD Cell Therapy Trial Deemed Surplus for FDA Approval
ProKidney, CKD, cell therapy, Phase 3 trial, FDA approval
Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success
Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding